Chemosensitivity testing of human tumors using Si-sensor chips

Area of Science:

• Oncology
• Biotechnology
• Medical Diagnostics

Background:

• Chemotherapy is a cornerstone of cancer treatment, but selecting the optimal agent for individual patients remains challenging.
• Numerous in vitro assays exist to predict chemosensitivity and chemoresistance, aiding drug screening and treatment planning.
• Current methods face limitations in terms of time, complexity, and direct correlation with clinical outcomes.

Purpose of the Study:

• To review the technology of silicon-sensor chips for assessing cellular metabolic changes in cancer research.
• To present recent applications of these sensors in evaluating drug efficacy using cell cultures, tissue slices, and biopsies.
• To highlight advancements in in vitro chemosensitivity testing for personalized cancer therapy.

Main Methods:

• Review of existing in vitro chemosensitivity and chemoresistance assays (cell viability, metabolism, clonogenic assays).
• Introduction of silicon-sensor chip technology, focusing on light-addressed potentiometric sensors (LAPS) and multisensor arrays (MSA).
• Discussion of sensor principles, including metabolic change detection, impedance, pH, O2, and temperature monitoring.

Main Results:

• Silicon-sensor chips enable real-time monitoring of metabolic activity in living cells.
• Multisensor arrays (MSA) allow for the simultaneous online measurement of multiple cellular parameters.
• These advanced sensors show promise for more accurate and efficient drug screening and chemosensitivity testing.

Conclusions:

• Silicon-sensor chip technology represents a significant advancement in in vitro cancer drug testing.
• These sensors facilitate a deeper understanding of cellular responses to chemotherapeutic agents.
• The technology holds potential for improving the selection of personalized cancer treatments and enhancing patient outcomes.